Virtual Library
Start Your Search
Rita Vitorino
Author of
-
+
P1.17 - Thymic Malignancies/Esophageal Cancer/Other Thoracic Malignancies (ID 703)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Thymic Malignancies/Esophageal Cancer/Other Thoracic Malignancies
- Presentations: 1
- Moderators:
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P1.17-012 - Thymic Neoplasms: The Experience of a Cancer Institute (ID 9603)
09:30 - 16:00 | Presenting Author(s): Rita Vitorino
- Abstract
Background:
Thymic epithelial neoplasms (TN), thymoma and thymic carcinoma are a rare heterogeneous category of lesions with a broad spectrum of pathologic characteristics and clinical presentations. The histologic classification and staging are complex and controversial; however they remain the most important prognostic factors to consider. Complete radical surgical resection remains the gold standard of therapy. Radiation and chemotherapy are important elements of the multimodality approach. The objective of this study is to describe demographic variables, staging, performed treatment and overall survival (OS) of patients diagnosed with TN followed in our institution, in the last 13 years.
Method:
Retrospective analysis of medical records of patients diagnosed with TN, followed in our cancer Institute from January 2004 to February 2017.
Result:
We followed 43 patients (22 female, and 21 male) with TN diagnose, 3 thymic carcinoma (1 squamous cell carcinoma) and 40 thymoma. The average age at diagnose was 52 years (min 22, max 84). 79% were symptomatic at diagnosis (45% with respiratory symptoms, no differences found for early and advanced stage). In 18,6%, the TN was associated with paraneoplastic autoimmune syndrome (7 pts Miastenia Gravis, 1 pt pure red cell aplasia). The most frequent performance status (ECOG scale) at diagnosis was 0 (41,8%) and 1 (48,8%). The majority of pts (60.4%) were at Masaoka stage I and II (13 pts each group). 6.9% stage III, 11.6% ( 5 pts) stage IVA and 20.9% (9 pts) stage IVB. Regarding to the OMS Classification, 27.9% were type AB, 16.3% type B1 and 11.6% type B2/B3. 81.4% of the patients were treated with surgery. 23.3% (10 pts) received chemotherapy (3 pts preoperative). 39.5% (17 pts) received adjuvant radiotherapy, and 7% pts received palliative radiotherapy. Overall survival (OS) at 5 years is 81%; at 10 years is 66%. The median survival time was 16,36 years (IC95%: 8,716 - 24,007). Disease progression was documented in 8 pts, with a median time to progression of 5,8 months. Median survival wasn’t reached for stage I, and for stage II, III, IVa, IVb was, respectively: 9,9 years, 5,76 years, 0,9 years and 6,4 years.
Conclusion:
In this retrospective study, we found an important percentage of pts symptomatic at diagnose, almost 20% with paraneoplastic syndromes, but with a good performance status. As expected most (86%) were treated with surgery, but many with a multimodal approach (46,5%). Prognosis is good even in stage IV disease.
